Oral Drug Delivery Articles

1. GenAI: The Muscle Behind Strong Regulatory Intelligence For Combination Products 3/2/2026

   In this article, combination product consultant Doug Mead provides the rationale and offers guidance for using GenAI tools to search regulatory databases. He shows the benefits for biopharma developers of conducting “precedent research” into previous regulatory pathways and results for similar or related drug delivery product submissions. 

2. Regulatory Precedents For Drug Delivery: Uncovering Clues To Successful Submissions 3/2/2026

   In this article, Chief Editor Tom von Gunden considers the need for and benefit of conducting AI-based research into regulatory precedents for drug delivery submissions and approvals. He consults combination products consultant Doug Mead on best practices in bolstering regulatory intelligence and regulatory approval success by way of advanced search methods. 

3. Rethinking Product Development Through Lipid-Based Formulations 2/24/2026

   Optimization of lipid-based drug formulation, when developed with the correct technology, can lead to major product performance enhancements that benefits patients.

4. Nanotechnology Drug Delivery: A Market Overview 1/6/2026

   New market research reveals the scientific, geopolitical, and business trends driving growth in the nanotechnology drug delivery market.

5. Combination: The Drug Delivery Word Of The Year For 2026 12/30/2025

   In this article, Chief Editor Tom von Gunden explains why he sees 2026 as the year combination products and therapies become fully central to drug and biologics product development, delivery, and regulatory. He points to personalized medicine and patient self-administration as key factors shaping his view of the drug delivery landscape.

6. Regulating For Patient Safety And Success With Combination Products 12/16/2025

   At the AFDO/RAPS Combination Products Summit 2025, a notable focus emerged around approaches to risk assessment and human factors studies. In this article, Chief Editor Tom von Gunden offers his appreciation for the biopharma industry’s consideration of patient usability and safety in the development and regulation of combination products and other drug delivery devices. 

7. Drug Delivery Trends From 2025: Top 4 For Momentum Gains In 2026 12/2/2025

   In this article, Fran DeGrazio identifies four notable trends in drug delivery that gained momentum in 2025 and, she predicts, will continue to do so in 2026 and beyond. They are digitalization, sustainability, patient centricity, and the advanced delivery of complex biopharmaceuticals.

8. M&A In GLP-1 Technology: Practical Recommendations And Best Practices 11/4/2025

   With explosive demand, expanding indications, and rapid innovation, the GLP-1 revolution is reshaping dealmaking. Here's a practical guide for companies negotiating M&A in this arena.

9. Drug Delivery Innovation: Getting Advanced Therapies To Patients 11/3/2025

   In this article, Fran DeGrazio recounts the evolution of drug delivery technologies as she underscores the need to innovate in the delivery of advanced therapies. Considering chronic diseases, rare diseases, and difficult-to-reach therapeutic targets, Fran offers suggestions for organizing and readying for the development and delivery of platforms, systems, and devices for next generation treatments, including personalized, precision medicines.

10. 7 Management Strategies For Combination Product Regulatory Success 9/2/2025

    In this article, Fran DeGrazio lays out best practices for biopharma executive leadership and non-technical managers to sustain regulatory momentum for their combination product development and commercialization. Fran points to cross-functional collaboration, quality management systems, regulatory documentation, and post-market surveillance as keys to drug delivery product success.